Compare Franco-Nevada Corporation (FNV) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs Medtronic PLC — how do they compare? Franco-Nevada Corporation trades at $236.47 (market cap $46.80B), while Medtronic PLC trades at $95.08 (market cap $118.97B). The key difference: Medtronic PLC is far larger — about 2.5× Franco-Nevada Corporation's market cap, and Medtronic PLC pays the higher dividend (3.1%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Medtronic PLC for 63 Days on average.
| FNV | MDT | |
|---|---|---|
Market Cap | $46.80B | $118.97B |
Volume | 310,692 | 24,932,018 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $105.35 |
52-Week Low | $183.97 | $73.75 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $45.79B | $138.31B |
Dividend Yield | 0.72% | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
Medtronic (MDT) trades at $93.01, up 1.17% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats, 7% revenue growth in Q1 2026, and a 49-year dividend growth streak. Valuation metrics include a P/E of 22.91 and P/S of 3.19. Recent positive news includes FDA clearances for medical devices and raised full-year guidance, supporting investor confidence.
Outlook remains positive with analyst consensus at Buy (61%) and $97.73 price target. Key opportunities include sustained dividend growth and new product approvals, while risks involve debt increase to 31.11% of assets and competitive pressures. The stock's current level near resistance at $93 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
